Please ensure Javascript is enabled for purposes of website accessibility

What Do We Know About Intuitive Surgical, Inc.'s Q4 Earnings?

By Anders Bylund - Jan 21, 2016 at 6:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We already have some of the basic numbers, but those never tell the whole story.

A nurse sets up the flagship da Vinci Xi system for a multi-site procedure. Photo: Intuitive Surgical.

Robotic-surgery veteran Intuitive Surgical (ISRG 1.00%) is set to report its final fourth-quarter 2015 results after the closing bell on Thursday. We already know nearly all of the basic figures, from the number of systems sold to approximate earnings, but the company may still have some surprises up its shiny metal sleeves.

What we know already
The company announced preliminary results on Jan. 13, containing most of the details that typically move stocks after their earnings reports.

So if expected results hold true, we know that total sales will grow roughly 12% year over year, landing near $677 million. Instrument and accessory revenues will jump 16% or so, representing more than 48% of Intuitive Surgical's total sales. That's up from 46.8% in the year-ago quarter.

About 652,000 surgical procedures were performed in 2015 using a da Vinci surgical system. That's a 14% increase from 2014. Looking ahead, Intuitive Surgical's management expects 9-12% procedure growth in 2016.

The company shipped 158 da Vinci systems in the fourth quarter, good for roughly $231 million in collected revenue. Only 16 systems will collect revenues over time under a lease agreement, but that's still a sharp increase from 5 leases in the same quarter of 2014.

System sales are surging in Asia and the U.S., but shrinking in Europe. Average selling prices are holding steady at $1.55 million per da Vinci system, and there are now 3,597 of these systems in service worldwide.

The approximate figures are still subject to audits and adjustments, and may come in slightly above or below the posted numbers. But we're in the right ballpark already, and the system sales figures are hard data. There won't be any major surprises on the income statement, with the caveat that Intuitive Surgical declined to provide any bottom-line guidance.

There, Wall Street analysts expect earnings of $5.00 per share. Now, they largely haven't adjusted their financial models to account for the preliminary results -- the revenue consensus is still stuck at just $653 million. In other words, the table seems set for a positive bottom-line surprise.

What we should be looking for
So we'll be looking for a solid earnings figure on Thursday, but that's not all.

In every earnings call, Intuitive Surgical CEO Gary Guthart likes to undated investors on what's next for the da Vinci system. In particular, he keeps us abreast on which approved procedures (by the FDA and similar regulatory bodies abroad) are rising in popularity, and which new procedures these regulators might approve next.

If that doesn't sound like a big deal, keep in mind that regulatory approvals outline the size of Intuitive Surgical's addressable market. Currently, the systems are largely limited to cancer-related organ removals, gynecological treatments, and various intestinal resections. These are respectably large markets, but there's a long list of potential expansions where da Vinci robots just haven't been allowed to make their mark yet.

In the third quarter, for example, Guthart pointed out strong growth in inguinal hernia repairs and prostatectomies. In China, Korea, Japan, and Europe, the robots blazed a trail of neurology procedures. These have not been approved by the FDA yet, but American regulators may pay attention to this growing body of overseas neurology treatments when they draw up rules for similar robot-assisted surgeries here.

Kidney removals may be next on the list in Japan, as that country's regulators are considering Intuitive Surgical's application for such procedures right now. Back home, the American College of Surgeons is considering a movable table for the da Vinci Xi machine, alongside a stabler attachment that would open up new procedure options in thoracic surgery (heart and lung treatments).

Look for fresh updates on these applications, and keep an eye out for further procedure expansions. These machines currently serve a very small niche market in the vast landscape of general surgery procedures, so new approvals are essential for Intuitive Surgical's long-term growth.

Intuitive Surgical shares have gained 16% over the past three months, lifted by a strong third-quarter report and a healthy market tenor in general. Meanwhile, the S&P 500 benchmark took an 8% dive. The stock jumped more than 4% when the preliminary results were published, that was without a bottom-line earnings figure.

Anders Bylund owns shares of Intuitive Surgical. The Motley Fool owns shares of and recommends Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$238.37 (1.00%) $2.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.